Fusion Pharmaceuticals Inc. announced the appointment of James J. O’Leary, M.D., as chief medical officer (CMO). Dr. O’Leary brings to Fusion more than 20 years of oncology industry experience including roles within biotechnology companies such as ImmunoGen, Idera Pharmaceuticals, Array Biopharma, and Deciphera, and pharmaceutical companies including Takeda, Bayer and Pfizer. During his time at Takeda, Dr. O’Leary was a global project team leader for a late stage asset directing global strategy and regulatory approvals. At ImmunoGen, he was the CMO and was responsible for guiding the strategic direction and execution of all clinical programs, including antibody-drug conjugates. Prior to joining the biopharmaceutical industry, Dr. O’Leary was a medical reviewer with the U.S. Food and Drug Administration. Before that, he was a practicing oncologist in New York.